The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Open accessAbstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTEvolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to ClinicDana V. Ferraris*View Author Information Johns Hopkins University Brain Science Institute, 855 N. Wolfe Street, Baltimore, Maryland 21205*Contact information. Phone: (410) 614-1107. Fax: (410) 614-0659. E-mail: [email protected]Cite this: J. Med. Chem. 2010, 53, 12, 4561–4584Publication Date (Web):April 5, 2010Publication History Received6 January 2010Published online5 April 2010Published inissue 24 June 2010https://doi.org/10.1021/jm100012mCopyright © 2010 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views7888Altmetric-Citations275LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit Read OnlinePDF (5 MB) Get e-AlertscloseSUBJECTS:Amides,Cancer,Cells,Genetics,Inhibitors Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,121
Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity
Zhang, J., Dawson, V. L., Dawson, T. M., & Snyder, S. H. (1994) · Science · doi:10.1126/science.8080500 · Cited by 1,118
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,056
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia
Eliasson, M. J. L., Sampei, K., Mandir, A. S., Hurn, P. D., Traystman, R. J., Bao, J., Pieper, A., Wang, Z.-Q., Dawson, T. M., Snyder, S. H., et al. (1997) · Nature Medicine · doi:10.1038/nm1097-1089 · Cited by 1,018
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.
Wang, Z. Q., Auer, B., Stingl, L., Berghammer, H., Haidacher, D., Schweiger, M., & Wagner, E. F. (1995) · Genes & Development · doi:10.1101/gad.9.5.509 · Cited by 774
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773
Audebert, M., Salles, B., & Calsou, P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404524200 · Cited by 707
Structure−Brain Exposure Relationships
Hitchcock, S. A., & Pennington, L. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060642i · Cited by 698
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 638
Ischemic Brain Injury is Mediated by the Activation of Poly(ADP-Ribose)Polymerase
Endres, M., Wang, Z.-Q., Namura, S., Waeber, C., & Moskowitz, M. A. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199711000-00002 · Cited by 622
Szabó, C., Zingarelli, B., O'Connor, M., & Salzman, A. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1753 · Cited by 622
XRCC1 and DNA strand break repair
Caldecott, K. W. (2003) · DNA Repair · doi:10.1016/s1568-7864(03)00118-6 · Cited by 598
Hassa, P. (2008) · Frontiers in Bioscience · doi:10.2741/2909 · Cited by 584
Menear, K. A., Adcock, C., Boulter, R., Cockcroft, X.-L., Copsey, L., Cranston, A., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001263 · Cited by 584
Novel inhibitors of poly(ADP-ribose) synthetase
Purnell, M. R., & Whish, W. J. (1980) · Biochemical Journal · doi:10.1042/bj1850775 · Cited by 527
Base Excision Repair Is Impaired in Mammalian Cells Lacking Poly(ADP-ribose) Polymerase-1
Dantzer, F., de la Rubia, G., Ménissier-de Murcia, J., Hostomsky, Z., de Murcia, G., & Schreiber, V. (2000) · Biochemistry · doi:10.1021/bi0003442 · Cited by 505
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487
Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase.
Banasik, M., Komura, H., Shimoyama, M., & Ueda, K. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45983-2 · Cited by 476
Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy
Bolli, R., Becker, L., Gross, G., Mentzer, R., Balshaw, D., & Lathrop, D. A. (2004) · Circulation Research · doi:10.1161/01.res.0000137171.97172.d7 · Cited by 428
Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 383
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 326
Jones, P., Altamura, S., Boueres, J., Ferrigno, F., Fonsi, M., Giomini, C., Lamartina, S., Monteagudo, E., Ontoria, J. M., Orsale, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901188v · Cited by 316
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Thomas, H. D., Calabrese, C. R., Batey, M. A., Canan, S., Hostomsky, Z., Kyle, S., Maegley, K. A., Newell, D. R., Skalitzky, D., Wang, L.-Z., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0552 · Cited by 303
Targeted therapy for cancer using PARP inhibitors
Lord, C. J., & Ashworth, A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.016 · Cited by 289
White, A. W., Almassy, R., Calvert, A. H., Curtin, N. J., Griffin, R. J., Hostomsky, Z., Maegley, K., Newell, D. R., Srinivasan, S., & Golding, B. T. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000950v · Cited by 288
Penning, T. D., Zhu, G.-D., Gandhi, V. B., Gong, J., Liu, X., Shi, Y., Klinghofer, V., Johnson, E. F., Donawho, C. K., Frost, D. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801171j · Cited by 268
O'Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B., & Bradley, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3 · Cited by 242
Abdelkarim, G., Gertz, K., Harms, C., Katchanov, J., Dirnagl, U., Szabo, C., & Endres, M. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.7.3.255 · Cited by 241
PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development
Huber, A., Bai, P., Murcia, J. M. D., & Murcia, G. D. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.06.002 · Cited by 222
Ogata, N., Ueda, K., Kagamiyama, H., & Hayaishi, O. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43873-8 · Cited by 212
Delaney, C. A., Wang, L. Z., Kyle, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomský, Z., & Newell, D. R. (2000) · PubMed · doi:10.25405/ncl.34597155 · Cited by 205
Tentori, L., Leonetti, C., Scarsella, M., d’Amati, G., Vergati, M., Portarena, I., Xu, W., Kalish, V. J., Zupi, G., Zhang, J., et al. (2003) · PubMed · Cited by 204
Ruf, A., de Murcia, G., & Schulz, G. E. (1998) · Biochemistry · doi:10.1021/bi972383s · Cited by 199
Jagtap, P., Soriano, F. G., Virág, L., Liaudet, L., Mabley, J., Szabó, É., Haskó, G., Marton, A., Lorigados, C. B., Gallyas, F., et al. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205000-00019 · Cited by 184
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases
Peralta-Leal, A., Rodríguez-Vargas, J. M., Aguilar-Quesada, R., Rodríguez, M. I., Linares, J. L., de Almodóvar, M. R., & Oliver, F. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.04.008 · Cited by 181
Poly(ADP-Ribose) Polymerase Inhibitors
Southan, G., & Szabó, C. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368376 · Cited by 180
DNA repair: PARP – another guardian angel?
Jeggo, P. A. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70032-6 · Cited by 179
Methods for Biochemical Study of Poly(ADP-Ribose) Metabolism in Vitro and in Vivo
Shah, G. M., Poirier, D., Duchaine, C., Brochu, G., Desnoyers, S., Lagueux, J., Verreault, A., Hoflack, J. C., Kirkland, J. B., & Poirier, G. G. (1995) · Analytical Biochemistry · doi:10.1006/abio.1995.1245 · Cited by 171
Cheng, C. L., Johnson, S. P., Keir, S. T., Quinn, J. A., Ali-Osman, F., Szabo, C., Li, H., Salzman, A. L., Dolan, M. E., Modrich, P., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0128 · Cited by 171
Russo, A. L., Kwon, H.-C., Burgan, W. E., Carter, D., Beam, K., Weizheng, X., Zhang, J., Slusher, B. S., Chakravarti, A., Tofilon, P. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2079 · Cited by 169
Epigenetics: poly(ADP‐ribosyl)ation of PARP‐1 regulates genomic methylation patterns
Caiafa, P., Guastafierro, T., & Zampieri, M. (2009) · The FASEB Journal · doi:10.1096/fj.08-123265 · Cited by 165
Targeting the DNA Damage Response in Cancer
Ljungman, M. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 163
Synthesis of New Indeno[1,2-c]isoquinolines: Cytotoxic Non-Camptothecin Topoisomerase I Inhibitors
Cushman, M., Jayaraman, M., Vroman, J. A., Fukunaga, A. K., Fox, B. M., Kohlhagen, G., Strumberg, D., & Pommier, Y. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000029d · Cited by 162
PolyADP‐ribosylation and cancer
Miwa, M., & Masutani, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00567.x · Cited by 161
Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors
Skalitzky, D. J., Marakovits, J. T., Maegley, K. A., Ekker, A., Yu, X., Hostomský, Z., Webber, S. E., Eastman, B. W., Almassy, R. J., Li, J., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255769 · Cited by 152
PARP Inhibitor Development for Systemic Cancer Targeting
Zaremba, T., & Curtin, N. J. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007781668715 · Cited by 144
Bowman, K. J., White, A. W., Golding, B. T., Griffin, R., & Curtin, N. J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.670 · Cited by 143
Koch, S. S. C., Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X., Zook, S. E., Kumpf, R. A., Zhang, C., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020259n · Cited by 141
Boulton, S. J., Pemberton, L., Porteous, J. K., Curtin, N. J., Griffin, R., Golding, B. T., & Durkacz, B. W. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.423 · Cited by 136
Ruthenium−Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity
Gianferrara, T., Bergamo, A., Bratsos, I., Milani, B., Spagnul, C., Sava, G., & Alessio, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1002588 · Cited by 130
Griffin, R. J., Srinivasan, S., Bowman, K. J., Calvert, H., Curtin, N. J., Newell, D. R., Pemberton, L., & Golding, B. T. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980273t · Cited by 127
Suto, M. J., Turner, W. R., Arundel-Suto, C. M., Werbel, L. M., & Sebolt, J. S. (1991) · PubMed · Cited by 112
Miyashiro, J. M., Woods, K. W., Park, C. H., Liu, X., Shi, Y., Johnson, E. F., Bouska, J. J., Olson, A. M., Luo, Y., Fry, E. H., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.016 · Cited by 107
Goldfarb, R. D., Marton, A., Szabó, É., Virág, L., Salzman, A. L., Glock, D., Akhter, I., McCarthy, R. J., Parrillo, J. E., & Szabó, C. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205000-00004 · Cited by 102
Miknyoczki, S. J., Chang, H., Grobelny, J. V., Pritchard, S., Worrell, C. S., McGann, N., Ator, M. A., Husten, J., Deibold, J., Hudkins, R. L., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0062 · Cited by 100
Hattori, K., Kido, Y., Yamamoto, H., Ishida, J., Kamijo, K., Murano, K., Ohkubo, M., Kinoshita, T., Iwashita, A., Mihara, K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0499256 · Cited by 99
Plummer, R., Lorigan, P. C., Evans, J., Steven, N. M., Middleton, M. R., Wilson, R., Snow, K., Dewji, R., & Calvert, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8013 · Cited by 98
Cuzzocrea, S. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.016 · Cited by 97
Inhibitor‐induced structural change of the active site of human poly(ADP‐ribose) polymerase
Kinoshita, T., Nakanishi, I., Warizaya, M., Iwashita, A., Kido, Y., Hattori, K., & Fujii, T. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01362-0 · Cited by 95
O’Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D. A., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B. M., & Bradley, C. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.3 · Cited by 95
Loh, V. M. J., Cockcroft, X. F., Dillon, K. J., Dixon, L., Drzewiecki, J., Eversley, P. J., Gomez, S., Hoare, J., Kerrigan, F., Matthews, I. T. W., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.026 · Cited by 94
Cockcroft, X. F., Dillon, K. J., Dixon, L., Drzewiecki, J., Kerrigan, F., Loh, V. M. J., Martin, N. M. B., Menear, K. A., & Smith, G. C. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.081 · Cited by 90
Drew, Y., & Plummer, R. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.10.001 · Cited by 88
Morrow, D. A., Brickman, C. M., Murphy, S. A., Baran, K. W., Krakover, R., Dauerman, H. L., Kumar, S., Slomowitz, N., Grip, L. T., McCabe, C. H., et al. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-008-0230-1 · Cited by 88
Ishida, J., Yamamoto, H., Kido, Y., Kamijo, K., Murano, K., Miyake, H., Ohkubo, M., Kinoshita, T., Warizaya, M., Iwashita, A., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.061 · Cited by 87
Tentori, L., Leonetti, C., Scarsella, M., d’Amati, G., Portarena, I., Zupi, G., Bonmassar, E., & Graziani, G. (2002) · Blood · doi:10.1182/blood.v99.6.2241 · Cited by 83
Xu, Z., Li, Y., Xiang, Q., Pei, Z., Liu, X., Lu, B., Chen, L., Wang, G., Pang, J., & Lin, Y. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1001502 · Cited by 82
Jagtap, P. G., Baloglu, E., Southan, G. J., Mabley, J. G., Li, H., Zhou, J., van Duzer, J., Salzman, A. L., & Szabó, C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0502891 · Cited by 82
Iwashita, A., Hattori, K., Yamamoto, H., Ishida, J., Kido, Y., Kamijo, K., Murano, K., Miyake, H., Kinoshita, T., Warizaya, M., et al. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.01.036 · Cited by 81
Penning, T. D., Zhu, G., Gandhi, V. B., Gong, J., Thomas, S. A., Lubisch, W., Grandel, R., Wernet, W., Park, C. H., Fry, E. H., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.05.044 · Cited by 78
Jagtap, P. G., Southan, G. J., Baloglu, E., Ram, S., Mabley, J. G., Marton, A., Salzman, A. L., & Szabó, C. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.007 · Cited by 76
Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor
Faro, R., Toyoda, Y., McCully, J. D., Jagtap, P. G., Szabó, É., Virág, L., Bianchi, C. F., Levitsky, S., Szabó, C., & Sellke, F. W. (2002) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(01)03329-x · Cited by 67
Bedikian, A. Y., Papadopoulos, N. E., Kim, K. B., Hwu, W., Homsi, J., Glass, M. R., Cain, S., Rudewicz, P. J., Vernillet, L., & Hwu, P. (2009) · Cancer Investigation · doi:10.1080/07357900802709159 · Cited by 67
Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide
Mendeleyev, J., Kirsten, E., Hakam, A., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00189-7 · Cited by 64
Chen, L., Wilson, D. J., Xu, Y., Aldrich, C. C., Felczak, K., Sham, Y. Y., & Pankiewicz, K. W. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100424m · Cited by 64
Kopetz, S., Mita, M. M., Mok, I., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3577 · Cited by 61
Watson, C. Y., WHISH, W. J. D., & Threadgill, M. D. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00029-7 · Cited by 60
Novel potent inhibitors of the DNA-repair enzyme poly (ADP-ribose)polymerase (PARP)
Griffin, R. J., Pemberton, L., Rhodes, D., Bleasdale, C., Bowman, K. J., Calvert, H., Curtin, N. J., Durkacz, B. W., Dr, N., Porteous, J. K., et al. (1995) · PubMed · doi:10.25405/ncl.34091328.v1 · Cited by 59
Inhibitors and activators of ADP-ribosylation reactions
Banasik, M., & Ueda, K. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928461 · Cited by 57
Parveen, I., Naughton, D. P., WHISH, W. J. D., & Threadgill, M. D. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00306-6 · Cited by 57
Ferraris, D. V., Ficco, R. P., Dain, D., Ginski, M. J., Lautar, S. L., Lee-Wisdom, K., Shi, L., Lin, Q., Lu, M. X.-C., Morgan, L. A., et al. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00333-x · Cited by 56
Self-citationOrvieto, F., Branca, D., Giomini, C., JONES, P. G., Koch, U., Ontoria, J. M., Palumbi, M. C., Rowley, M., Toniatti, C., & Muraglia, E. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.113 · Cited by 56
Saffhill, R., & Ockey, C. H. (1985) · Chromosoma · doi:10.1007/bf00348697 · Cited by 55
Triple-negative breast cancer: Novel therapies and new directions
Pal, S. K., & Mortimer, J. E. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.06.010 · Cited by 54
Mahany, J. J., Lewis, N., Heath, E. I., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3579 · Cited by 51
Lukas, R. J., Muresan, A. Z., Damaj, M. I., Blough, B. E., Huang, X., Navarro, H. A., Mascarella, S. W., Eaton, J. B., Marxer-Miller, S., & Carroll, F. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1003232 · Cited by 50
Tikhe, J. G., Webber, S. E., Hostomský, Z., Maegley, K. A., Ekkers, A., Li, J., Yu, X., Almassy, R. J., Kumpf, R. A., Boritzki, T. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030513r · Cited by 49
Synthesis and structure–activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors
Tao, M., Park, C. H., Bihovsky, R., Wells, G. J., Husten, J., Ator, M. A., & Hudkins, R. L. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.099 · Cited by 48
INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin
Mason, K. A., Valdecanas, D. R., Hunter, N. R., & Milas, L. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9072-5 · Cited by 46
Zhu, G., Gandhi, V. B., Gong, J., Thomas, S. A., Luo, Y., Liu, X., Shi, Y., Klinghofer, V., Johnson, E. F., Frost, D. J., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.023 · Cited by 44
GPI 6150 Prevents H2O2 Cytotoxicity by Inhibiting Poly(ADP-ribose) Polymerase
Zhang, J., Lautar, S. L., Huang, S. H., Ramsey, C., Cheung, A., & Li, J.-H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3816 · Cited by 44
Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase
Menear, K. A., Adcock, C., Alonso, F. C., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.025 · Cited by 41
Martínez‐Romero, R., Martínez‐Lara, E., Aguilar‐Quesada, R., Peralta, A., Oliver, F. J., & Siles, E. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21781 · Cited by 40
Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
Papeo, G., Forte, B., Orsini, P., Perrera, C., Posteri, H., Scolaro, A., & Montagnoli, A. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903215883 · Cited by 38
Ferraris, D. V., Ficco, R. P., Pahutski, T. F., Lautar, S. L., Huang, S. H., Zhang, J., & Kalish, V. J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00465-7 · Cited by 31
Self-citationNew inhibitors of poly(ADP-ribose) polymerase (PARP)
Peukert, S., & Schwahn, U. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.11.1531 · Cited by 29
Kamanaka, Y., Kondo, K., Ikeda, Y., Kamoshima, W., Kitajima, T., Suzuki, Y., Nakamura, Y., & Umemura, K. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.057 · Cited by 23
Ikeda, Y., Hokamura, K., Kawai, T., Ishiyama, J., Ishikawa, K., Anraku, T., Uno, T., & Umemura, K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.08.046 · Cited by 17
Moree, W. J., Goldman, P., DeMaggio, A. J., Christenson, E., Herendeen, D., Eksterowicz, J. E., Kesicki, E. A., McElligott, D. L., & Beaton, G. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.091 · Cited by 14
Cited by
Mouchiroud, L., Houtkooper, R. H., Moullan, N., Katsyuba, E., Ryu, D., Cantó, C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.016 · Cited by 1,210
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
Thorsell, A.-G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., Moche, M., Cohen, M. S., & Schüler, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 358
Metadata
- Authors
- Ferraris, D. V.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-04-05
- Volume
- 53
- Issue
- 12
- Pages
- 4561-4584
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1993582972
- Cited by
- 363
- References
- 108
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.